Multivariate analysis predictive factors for the outcome of allogeneic HSCT in patients with MDS
| Clinical variables . | Overall survival . | Probability of relapse . | Nonrelapse mortality . | |||
|---|---|---|---|---|---|---|
| HR* . | P . | HR . | P . | HR . | P . | |
| Recipient gender (male vs female) | 1.19 | .19 | 1.14 | .54 | 1.34 | .10 |
| Recipient age (≥50 vs <50 years) | 1.46 | .02 | 1.08 | .76 | 1.79 | .02 |
| IPSS-R risk | 1.41 | <.001 | 1.81 | <.001 | 1.16 | .12 |
| HCT-CI* (high risk vs low/intermediate) | 1.52 | .03 | 1.03 | .91 | 1.83 | .017 |
| Monosomal karyotype (present vs absent) | 1.81 | .001 | 2.23 | .001 | .98 | .47 |
| Disease stage at transplantation (active/progressive disease vs complete remission) | 1.66 | .01 | 1.94 | .001 | 1.08 | .67 |
| Source of hematopoietic stem cells (bone marrow vs peripheral blood) | 1.10 | .49 | .87 | .48 | .88 | .50 |
| Type of donor (MUD vs HLA-identical sibling) | 1.68 | .001 | .86 | .62 | 2.21 | <.001 |
| Conditioning regimen (reduced-intensity vs standard conditioning) | .91 | .55 | 1.82 | .01 | .53 | .012 |
| Clinical variables . | Overall survival . | Probability of relapse . | Nonrelapse mortality . | |||
|---|---|---|---|---|---|---|
| HR* . | P . | HR . | P . | HR . | P . | |
| Recipient gender (male vs female) | 1.19 | .19 | 1.14 | .54 | 1.34 | .10 |
| Recipient age (≥50 vs <50 years) | 1.46 | .02 | 1.08 | .76 | 1.79 | .02 |
| IPSS-R risk | 1.41 | <.001 | 1.81 | <.001 | 1.16 | .12 |
| HCT-CI* (high risk vs low/intermediate) | 1.52 | .03 | 1.03 | .91 | 1.83 | .017 |
| Monosomal karyotype (present vs absent) | 1.81 | .001 | 2.23 | .001 | .98 | .47 |
| Disease stage at transplantation (active/progressive disease vs complete remission) | 1.66 | .01 | 1.94 | .001 | 1.08 | .67 |
| Source of hematopoietic stem cells (bone marrow vs peripheral blood) | 1.10 | .49 | .87 | .48 | .88 | .50 |
| Type of donor (MUD vs HLA-identical sibling) | 1.68 | .001 | .86 | .62 | 2.21 | <.001 |
| Conditioning regimen (reduced-intensity vs standard conditioning) | .91 | .55 | 1.82 | .01 | .53 | .012 |
Clinical and demographic variables were evaluated at the time of transplant in patients receiving allogeneic HSCT upfront and before remission-induction chemotherapy in patients receiving treatment before transplant. HR represents the relative risk of the first category with the respect to the last one (reference category).
HCT-CI as defined by Sorror et al.22